MADD Protein: A Potential Drug Target for Neuronal Tumors (G8567)

Target Name: MADD

NCBI ID: G8567

MADD

MADD Protein: A Potential Drug Target for Neuronal Tumors

Malignant Async (MADD) is a protein observed in neurons whose expression levels are significantly higher than in normal cells during both normal and tumor growth of neurons. MADD is a protein caused by genetic mutations. Its mutations lead to abnormal neuronal cell cycle, cell cycle arrest, and uncontrolled cell proliferation and apoptosis, leading to the occurrence of neuronal tumors.

Effects of MADD gene mutations

MADD gene mutations can cause neuronal cell cycle arrest, inhibited cell proliferation, and excessive apoptosis, leading to changes in the protein composition in the neuron nucleus and cytoplasm. These proteins include cell cycle proteins, cell adhesion proteins, nerve growth factors, etc. Their abnormal expression is an important reason for the occurrence of MADD tumors.

MADD protein expression levels

The expression level of MADD protein is an important indicator of neuronal tumorigenesis. Studies have found that the expression level of MADD protein is significantly higher than that of normal cells during both normal and tumor growth of neurons. The expression level of MADD protein is closely related to neuronal proliferation, apoptosis and cell cycle.

Detection of MADD tumors

The detection of MADD tumors is of great significance for studying the pathogenesis of MADD tumors. Currently, researchers use a variety of methods to detect the expression level of MADD protein, including immunohistochemistry, gene knockout, proteomics, etc. These methods can not only detect the expression level of MADD protein, but also detect the localization and expression pattern of MADD protein in neuronal tumor tissues, providing important basis for the diagnosis and treatment of neuronal tumors.

Treatment of MADD tumors

The treatment of MADD tumors is an important area of 鈥嬧?媟esearch. Researchers are exploring using the MADD protein as a drug target to treat neuronal tumors. Currently, some studies are exploring the use of anti-MADD drugs to inhibit the growth and spread of neuronal tumors. These drugs include anti-MADD drugs, anti-MADD antibodies, MADD-specific drugs, etc. These drugs can significantly inhibit the growth and spread of neuronal tumors and provide important help in the treatment of neuronal tumors.

The significance of MADD protein

MADD protein is an important protein that plays an important role in the occurrence of neuronal tumors. The expression level of MADD protein can be used as an important biomarker for neuronal tumors and can be used for the diagnosis and treatment of neuronal tumors. At the same time, MADD protein can also be used as a drug target to treat neuronal tumors.

Protein Name: MAP Kinase Activating Death Domain

Functions: Guanyl-nucleotide exchange factor that regulates small GTPases of the Rab family (PubMed:20937701, PubMed:18559336). Converts GDP-bound inactive form of RAB27A and RAB27B to the GTP-bound active forms (PubMed:20937701, PubMed:18559336). Converts GDP-bound inactive form of RAB3A, RAB3C and RAB3D to the GTP-bound active forms, GTPases involved in synaptic vesicle exocytosis and vesicle secretion (By similarity). Plays a role in synaptic vesicle formation and in vesicle trafficking at the neuromuscular junction (By similarity). Involved in up-regulating a post-docking step of synaptic exocytosis in central synapses (By similarity). Probably by binding to the motor proteins KIF1B and KIF1A, mediates motor-dependent transport of GTP-RAB3A-positive vesicles to the presynaptic nerve terminals (By similarity). Plays a role in TNFA-mediated activation of the MAPK pathway, including ERK1/2 (PubMed:32761064). May link TNFRSF1A with MAP kinase activation (PubMed:9115275). May be involved in the regulation of TNFA-induced apoptosis (PubMed:11577081, PubMed:32761064)

The "MADD Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MADD comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets